2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Endogenous Metabolite
  5. Endogenous Metabolite Isoform
  6. Endogenous Metabolite Inhibitor

Endogenous Metabolite Inhibitor

Endogenous Metabolite Inhibitors (50):

Cat. No. Product Name Effect Purity
  • HY-B1232
    Metyrapone
    		Inhibitor 99.83%
    Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression.
  • HY-106024B
    Alagebrium chloride
    		Inhibitor 99.82%
    Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor.
  • HY-B0251
    Eplerenone
    		Inhibitor 99.81%
    Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV).
  • HY-W012977
    3,3-Dimethyl-1-butanol
    		Inhibitor 99.56%
    3,3-Dimethyl-1-butanol (DMB) is an orally active inhibitor of trimethylamine (TMA) and trimethylamine N-oxide (TMAO). 3,3-Dimethyl-1-butanol inhibits the signaling pathway of p65 NF-κB and TGF-β1/Smad3. 3,3-Dimethyl-1-butanol has potential applications in cardiovascular disease (CVD).
  • HY-150252A
    ATIC-IN-1 acetate
    		Inhibitor 99.96%
    ATIC-IN-1 (compound 14) acetate is an inhibitor targeting to Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization with a Ki value of 685 nM, whcich catalyzes de novo purine biosynthesis. ATIC dimerization is crucial for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. ATIC-IN-1 acetate exhibits anti-tumor activity via reduction in cell numbers and cell division rates.
  • HY-155157
    PF-07247685
    		Inhibitor 98.66%
    PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC50=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice.
  • HY-137243
    Adenosine 3',5'-diphosphate disodium
    		Inhibitor 99.12%
    Adenosine 3',5'-diphosphate disodium is an endogenous purine nucleotide. Adenosine 3',5'-diphosphate disodium acts as an inhibitor of bovine adrenal estrogen sulfotransferase (EST) with a Ki value of 7.0 μM. It also serves as an indispensable specific cofactor for the pregnenolone-binding protein (PBP) steroid-binding complex, with an EC50 value of 1.5 μM in guinea pigs.
  • HY-171036
    GAPDH-IN-1
    		Inhibitor 98.10%
    GAPDH-IN-1 (Compound F8) is a GAPDH inhibitor (IC50 of 39.31 μM for GAPDH enzymatic activity). GAPDH-IN-1 forms a covalent adduct with an aspartic acid in the active site to displace NAD+, a cofactor of the enzyme, with concomitant enhancement of the cysteine-reactive probe reaction with the catalytic cysteine.
  • HY-B0251R
    Eplerenone (Standard)
    		Inhibitor
    Eplerenone (Standard) is the analytical standard of Eplerenone. This product is intended for research and analytical applications. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV).
  • HY-13749S1
    Sitagliptin-d4 hydrochloride
    		Inhibitor 99.36%
    Sitagliptin-d4 hydrochloride is the deuterium labeled Sitagliptin hydrochloride (HY-13749E). Sitagliptin hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes.
  • HY-32004
    Coumalic acid
    		Inhibitor
    Coumalic acid is an inhibitor of human carbonic anhydrase (hCA) (KI = 0.073 μM for hCA IX; KI = 0.083 μM for hCA XII). Coumalic acid is a valuable platform compound which can be prepared from malic acid. Coumalic acid can be used in the flavorings, fragrances and cosmetics industries, as polymer components, and pharmaceutical scaffolds. Coumalic acid displays antibronchial and antimalarial activity.
  • HY-118143
    AG-1801
    		Inhibitor 99.88%
    AG-1801, a nitrobenzopyridine derivative, is a tyrosine phosphorylation inhibitor. AG-1801 can induce the disintegration of the microtubule network in living cells, and does not inhibit microtubule polymerization in vitro. AG-1801 can be used for the study of microtubule-related signaling pathways.
  • HY-N9279
    Dehydromonocrotaline
    		Inhibitor
    Dehydromonocrotaline is a mitochondrial respiratory chain complex I NADH oxidase inhibitor, with a IC50 of 62.06 μM and a Ki of 8.1 μM in rats. Dehydromonocrotaline exerts non-competitive inhibitory effects by modifying cysteine thiol groups on complex I, and does not bind to the NADH-binding site. Dehydromonocrotaline dissipates mitochondrial membrane potential and reduces ATP levels. Dehydromonocrotaline can be used in studies related to hepatotoxicity, pulmonary hypertension and liver tumors.
  • HY-155156
    PF-07238025
    		Inhibitor 99.46%
    PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice.
  • HY-137823
    4-Nitrophenyl-N-acetyl-β-D-galactosaminide
    		Inhibitor 99.55%
    4-Nitrophenyl-N-acetyl-β-D-galactosaminide has inhibitory activity against GlcNAc and GalNAc with Kis of 1.15 mM and 0.51 mM, respectively. 4-Nitrophenyl-N-acetyl-β-D-galactosaminide is extracted from Trichomonas foetus (T. foetus)
  • HY-W590849
    F1874-108
    		Inhibitor 99.22%
    F1874-108 is an inhibitor of brassinosteroid biosynthesis and signal transduction.
  • HY-13749AR
    Sitagliptin phosphate (Standard)
    		Inhibitor
    Sitagliptin (MK-0431) phosphate (Standard) is the analytical standard of Sitagliptin phosphate (HY-13749A). This product is intended for research and analytical applications. Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.
  • HY-118483
    Benziodarone
    		Inhibitor
    Benziodarone is a potent inhibitor of S-arylglutathione transferase enzyme system. Benziodarone catalyzes BSP conjugation with GSH. Benziodarone inhibits biliary excretion of synthetic BSP-GSH conjugates.
  • HY-146036
    NADH-IN-1
    		Inhibitor 99.38%
    NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes.
  • HY-157528
    CJ28
    		Inhibitor 99.21%
    CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis.